Author:
Ferrario Alessandra,Arāja Diāna,Bochenek Tomasz,Čatić Tarik,Dankó Dávid,Dimitrova Maria,Fürst Jurij,Greičiūtė-Kuprijanov Ieva,Hoxha Iris,Jakupi Arianit,Laidmäe Erki,Löblová Olga,Mardare Ileana,Markovic-Pekovic Vanda,Meshkov Dmitry,Novakovic Tanja,Petrova Guenka,Pomorski Maciej,Tomek Dominik,Voncina Luka,Haycox Alan,Kanavos Panos,Vella Bonanno Patricia,Godman Brian
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference49 articles.
1. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2014;124:39–47.
2. Howard DHBP, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.
3. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research.
http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1
. Accessed 22 Feb 2017.
4. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between health care payers and manufacturers. Health Policy. 2010;96(3):179–90.
5. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels, Belgium: EMiNet. 2013.
http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf
. Accessed 22 Feb 2017.
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献